The early evaluation of lowGdose CT perfusion imaging for the treatment efficacy of lung cancer with anrotinib hydrochloride
10.3969/j.issn.1002G1671.2019.06.031
- VernacularTitle:低剂量CT灌注成像对盐酸安罗替尼治疗肺癌疗效的早期评估
- Author:
Lijing FAN
1
;
Xuejun CHEN
;
You YUN
;
Xiaoxian ZHANG
;
Lifeng WANG
;
Xiaoyan WEI
;
Weili XIA
;
Hailiang LI
Author Information
1. 郑州大学附属肿瘤医院放射科
- Keywords:
nonGsmall cell lung cancer;
perfusion imaging;
tumor regression rate;
antiangiogenic therapy
- From:
Journal of Practical Radiology
2019;35(6):977-980
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore whether CT perfusion imaging (CTPI)parameters can early predict the curative effect of anlotinib hydrochloride and their predictive accuracy for the treatment in lung cancer patients.Methods 2 6 patients with advanced nonGsmall cell lung cancer (NSCLC)were treated with anlotinib hydrochloride and underwent CTPI scanning before chemotherapy,after the first and second treatment cycle respectively.The average values of perfusion value (PV),peak enhancement image (PEI),time to peak (TTP),blood volume (BV)and the change rate of these parameters after one treatment cycle every time were measured and recorded. According to the response evaluation criteria in solid tumors 1.1 (RECIST1.1),the maximum diameter of the target tumor was measured and the tumor regression rate after two treatment cycles was calculated.Then a correlation analysis was conducted between the change rate of perfusion parameters (PV%,PEI%,TTP%,BV%)after one treatment cycle and the tumor regression rate (D%)after two treatment cycles. The ROC curve was performed to evaluate the accuracy of those parameters.Results PV after one treatment cycle was significantly lower than that before treatment,and PV% showed a statistical difference (P＝0.00).The PV% after one treatment cycle was positively correlated with D% after two treatment cycles (r＝0.56).In addition,the AUC of PV% and BV% were 0.99 and 0.88 respectively, and specificity were both 100%,with sensitivity respectively 75.7% and 82.6%.Conclusion CTPI can early reflect the curative effect of anlotinib hydrochloride for advanced NSCLC and provide more options for clinical evaluation.
